Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01426841

Enrollment

Registered

2011-09-01

Start date

2011-08-31

Completion date

2015-04-30

Last updated

2014-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Keywords

Small cell lung cancer, Adaptive radiotherapy, Thoracic radiotherapy

Brief summary

This study is intended to assess the feasibility of adjusting a radiation plan during its course to accommodate for a shrinking tumor target. The investigators hypothesize that an adaptive radiotherapy (RT) planning strategy for small cell lung cancer (SCLC) patients with chest-confined disease will allow for safe delivery of higher doses of chest RT than a non-adaptive RT planning approach without subjecting normal critical structures to unacceptable doses of radiotherapy.

Interventions

RADIATIONAdaptive Radiation

Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with histologically or cytologically proven newly diagnosed small cell lung cancer * chest-confined disease (including bulky intrathoracic disease) * adequate pulmonary function tests (FEV-1\>1.0 L, DLCO\>50%) * patients of childbearing potential must practice adequate contraception * Age \> or = 18 years * Karnofsky performance status \> or = 70 * eligible for concurrent chemoradiotherapy

Exclusion criteria

* patients who have undergone complete or subtotal tumour resection * evidence of non-small cell histology * prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for at least 5 years * prior RT to the thorax or neck * compromised lung function with inadequate pulmonary function tests (FEV-1\<1.0,DLCO\<50%) * pregnant women

Design outcomes

Primary

Measure	Time frame	Description
Differences in normal structure/target volume doses achievable using adaptive radiotherapy approach	12-24 months	Differences in normal structure/target volume doses achievable using adaptive radiotherapy approach will be measured in centigray

Secondary

Measure	Time frame	Description
Local control and patterns of failure	12-24 months	Local control and patterns of failure
Survival	12-24 months	—

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026